Press release

Press release

November 12, 2018

Follicum expands patent portfolio: First diabetes patent published and promising experimental data supports new patent application

Lund, Sweden, November 12, 2018. Follicum AB (“Follicum” or “the Company”) today announced that the company’s diabetes project is progressing according to plan and that the company has submitted a new patent application. Experimental studies show that the company’s new optimized peptides exert a protective and preservative effect on beta cells exposed to high glucose […]

August 29, 2018

Lund University research group receives follow-on DKK 1 million grant from Novo Nordisk Foundation for diabetes-related studies with Follicum peptides

Follicum AB (“Follicum”) today announced that Professor Jan Nilsson’s research team at Lund University has received an additional DKK 1,000,000 funding from the Novo Nordisk Foundation for carrying out preclinical studies for Follicum’s diabetes project based on modified osteopontin-related peptides. This represents a follow-on grant from the estimated DKK 400,000 the group received in 2017. […]

August 28, 2018

Follicum AB announces that all patients have completed the treatment with FOL-005 in the Phase IIa study against hair loss. Top-line data will be presented in the autumn.

Follicum AB (“Follicum” or “The Company”) today announces that all patients in the ongoing Phase IIa study with FOL-005 for hair loss have completed the treatment and finalized clinic visits. The Phase IIa study examines the safety and therapeutic effect of various doses of drug candidate FOL-005, administered as injections into the scalp. Follicum’s Phase […]

July 31, 2018

Follicum AB receives Notice of Allowance from the U.S. Patent Office for Enhanced Protection of Product Candidate FOL-005

Follicum AB (“Follicum”) announces that the U.S. Patent Office (USPTO) has issued a Notice of Allowance for their patent application 15/184,290 which is the company’s second, follow-up application which when granted confers expanded protection for Follicum’s product candidate FOL-005. Follicum has already an approved US patent in this patent family, specifically covering FOL-005. Follicum has […]

June 26, 2018

Major milestone – Follicum successfully develops direct-to-scalp formulation to replace intradermal injections for first-in-class peptide-based FOL-005 hair loss drug candidate

Follicum AB (“Follicum” or “Company”) today announced that the company has developed a new cosmetically appealing direct-to-scalp formulation of its leading peptide drug candidate FOL-005 for topical treatment of hair loss which will be used in future clinical trials. In Follicum’s ongoing Phase IIa study, patients with hair loss are being treated with intradermal injections […]

June 4, 2018

Follicum’s Phase IIa Hair Growth Study Fully Recruited

Follicum AB (“Follicum” or “the Company”) today announced that all patients in the Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. The trial is conducted at the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and Bioskin, Hamburg, Germany. The objective is to investigate the safety and […]